BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37053535)

  • 1. Trametinib in Patients With
    Wisinski KB; Flamand Y; Wilson MA; Luke JJ; Tawbi HA; Hong F; Mitchell EP; Zwiebel JA; Chen H; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Behrens RJ; Pennington KP; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    JCO Precis Oncol; 2023 Apr; 7():e2200421. PubMed ID: 37053535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chloroquine Sensitizes
    Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
    Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
    Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
    Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis.
    Sheng X; Kong Y; Li Y; Zhang Q; Si L; Cui C; Chi Z; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Dai J; Guo J
    Eur J Cancer; 2016 Sep; 65():156-63. PubMed ID: 27498141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dabrafenib and Trametinib in Patients With Tumors With
    Salama AKS; Li S; Macrae ER; Park JI; Mitchell EP; Zwiebel JA; Chen HX; Gray RJ; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Armstrong DK; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    J Clin Oncol; 2020 Nov; 38(33):3895-3904. PubMed ID: 32758030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and clinico-pathologic analysis of metastatic uveal melanoma.
    Griewank KG; van de Nes J; Schilling B; Moll I; Sucker A; Kakavand H; Haydu LE; Asher M; Zimmer L; Hillen U; Thompson JF; Scolyer RA; Schadendorf D; Murali R
    Mod Pathol; 2014 Feb; 27(2):175-83. PubMed ID: 23887304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131).
    Johnson DB; Zhao F; Noel M; Riely GJ; Mitchell EP; Wright JJ; Chen HX; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    Clin Cancer Res; 2020 Apr; 26(8):1812-1819. PubMed ID: 31924734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
    Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
    Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
    Kim KB; Kefford R; Pavlick AC; Infante JR; Ribas A; Sosman JA; Fecher LA; Millward M; McArthur GA; Hwu P; Gonzalez R; Ott PA; Long GV; Gardner OS; Ouellet D; Xu Y; DeMarini DJ; Le NT; Patel K; Lewis KD
    J Clin Oncol; 2013 Feb; 31(4):482-9. PubMed ID: 23248257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GNAS, GNAQ, and GNA11 alterations in patients with diverse cancers.
    Parish AJ; Nguyen V; Goodman AM; Murugesan K; Frampton GM; Kurzrock R
    Cancer; 2018 Oct; 124(20):4080-4089. PubMed ID: 30204251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic GNAQ and GNA11 mutations in uveal melanoma in Chinese.
    Xu X; Wei WB; Li B; Gao F; Zhang Z; Jonas JB
    PLoS One; 2014; 9(10):e109699. PubMed ID: 25280020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Driver mutations in
    García-Mulero S; Fornelino R; Punta M; Lise S; Varela M; Del Carpio LP; Moreno R; Costa-García M; Rieder D; Trajanoski Z; Gros A; Alemany R; Piulats JM; Sanz-Pamplona R
    Oncoimmunology; 2023; 12(1):2261278. PubMed ID: 38126027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.
    Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A
    Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uveal Melanoma:
    Psinakis F; Katseli A; Koutsandrea C; Frangia K; Florentin L; Apostolopoulou D; Dimakopoulou K; Papakonstantinou D; Georgopoulou E; Brouzas D
    Anticancer Res; 2017 Oct; 37(10):5719-5726. PubMed ID: 28982892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.
    Ominato J; Fukuchi T; Sato A; Yamaguchi N; Kobayashi K; Cho H; Oyama T; Ajioka Y
    Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):658-663. PubMed ID: 28248732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.
    Lyu J; Wu Y; Li C; Wang R; Song H; Ren G; Guo W
    J Oral Pathol Med; 2016 Apr; 45(4):295-301. PubMed ID: 26399561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
    Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
    Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
    Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in GNA11 in uveal melanoma.
    Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC
    N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.